You may remember that not so long ago I wrote about what looked like a drug discovery success story for pain: anti-NGF therapy for osteoarthritis. Well, it looks like that success was short-lived. Somehow I missed this over the Christmas break, but, the FDA has ended trials on anti-NGF therapies for osteoarthritis due to development of avascular necrosis in some patients. Nothing positive can come of avascular necrosis and the pulling of several trials would suggest that this is a drug class effect (or at least suspected to be). Anyway you cut it, this is bad news.
- Short blog post on our work on AMPK activators for chronic pain: bodyinmind.org/ampk-metformin… 2 years ago
- NIH spends less than $0.50 per migraine patient on migraine research americanmigrainefoundation.org/support-the-fo… 3 years ago
- New article by yours truly on Pain Research Forum... What's up with PKMzeta? painresearchforum.org/news/23452-wha… 3 years ago
- or this one: informahealthcare.com/doi/abs/10.310… Thanks a ton 3 years ago
- anyone have access to this? onlinelibrary.wiley.com/doi/10.1016/j.… PDF to juniorprofblog at gmail dot com 3 years ago
- New Facebook page for University of Arizona Department of Pharmacology on.fb.me/OWPl1v 4 years ago
jim on What is hyperalgesia? What is… email@example.com on Talking Tylenol… yes, mo… firstname.lastname@example.org on Talking Tylenol… yes, mo… email@example.com on Talking Tylenol… yes, mo… firstname.lastname@example.org on Talking Tylenol… yes, mo…
- What is hyperalgesia? What is allodynia?
- What is Central Sensitization?
- The most recent grant rejection letter
- Your postdoc mentor should be an effective advocate for your career development...
- A new mechanism of action for Selective Serotonin Reuptake Inhibitors (SSRIs)?: Pharm 551A, Baudry et al., 2010
- 447,699 fans